Scarica l'app Stockscreener
4.30
1.83%
-0.08
Dopo l'orario di chiusura:
4.42
0.12
+2.79%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché FBIO Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$4.38
Aprire:
$4.4
Volume 24 ore:
914.35K
Relative Volume:
1.78
Capitalizzazione di mercato:
$133.46M
Reddito:
$80.97M
Utile/perdita netta:
$-78.31M
Rapporto P/E:
-0.3879
EPS:
-11.0849
Flusso di cassa netto:
$-129.56M
1 W Prestazione:
+6.70%
1M Prestazione:
+51.41%
6M Prestazione:
+116.08%
1 anno Prestazione:
+106.73%
Intervallo 1D:
$4.29
$4.53
Intervallo di 1 settimana:
$4.015
$4.53
Portata 52W:
$1.325
$4.53
Fortress Biotech Inc Stock (FBIO) Company Profile
Nome
Fortress Biotech Inc
Settore
Industria
Telefono
781-652-4500
Indirizzo
1111 KANE CONCOURSE, BAY HARBOR ISLANDS, NY
Confronta FBIO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
FBIO
Fortress Biotech Inc
|
4.30 | 135.95M | 80.97M | -78.31M | -129.56M | -11.08 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Fortress Biotech Inc Stock (FBIO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-03-15 | Ripresa | ROTH MKM | Buy |
| 2022-08-04 | Iniziato | Ladenburg Thalmann | Buy |
| 2020-10-02 | Iniziato | The Benchmark Company | Buy |
| 2019-12-18 | Iniziato | B. Riley FBR | Buy |
| 2018-02-28 | Iniziato | B. Riley FBR, Inc. | Buy |
| 2017-07-11 | Iniziato | Rodman & Renshaw | Buy |
| 2017-03-22 | Iniziato | JMP Securities | Mkt Outperform |
| 2016-10-03 | Iniziato | ROTH Capital | Buy |
Mostra tutto
Fortress Biotech Inc Borsa (FBIO) Ultime notizie
Fortress Biotech (NASDAQ:FBIO) Stock Price Crosses Above 200 Day Moving Average – What’s Next? - Defense World
Aug Rallies: Can Fortress Biotech Inc. stock hit record highs againBond Market & AI Optimized Trade Strategies - ulpravda.ru
Will Fortress Biotech Inc.(CNB0) stock rise with strong economyJuly 2025 Volume & Consistent Return Strategy Ideas - ulpravda.ru
Can Fortress Biotech Inc. stock hit record highs againMarket Movement Recap & Daily Profit Maximizing Tips - ulpravda.ru
Will Fortress Biotech Inc. stock outperform international peersJuly 2025 Review & Expert Verified Stock Movement Alerts - ulpravda.ru
Will Fortress Biotech Inc. stock benefit from AI adoptionEarnings Recap Report & Community Verified Swing Trade Signals - ulpravda.ru
Is Fortress Biotech Inc.(CNB0) stock testing key supportWeekly Investment Report & Stepwise Entry/Exit Trade Alerts - ulpravda.ru
Fortress Biotech amends credit agreement with Oaktree - MSN
Head-To-Head Comparison: Fortress Biotech (NASDAQ:FBIO) & WAVE Life Sciences (NASDAQ:WVE) - Defense World
Journey Medical Corporation Announces Positive Topline Results from its Two Phase 3 Clinical Trials (MVOR-1 and MVOR-2) Evaluating DFD-29 for the Treatment of Papulopustular Rosacea in Adults - ADVFN
Fortress Biotech (NASDAQ:FBIO) Stock Price Passes Above Two Hundred Day Moving AverageWhat's Next? - MarketBeat
How Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (FBIOP) Affects Rotational Strategy Timing - Stock Traders Daily
Signal Recap: Will Fortress Biotech Inc stock benefit from AI adoptionMarket Sentiment Report & Consistent Profit Trading Strategies - moha.gov.vn
Fortress Biotech (NASDAQ:FBIO) Stock Price Passes Above 200-Day Moving AverageHere's What Happened - MarketBeat
What analysts say about Fortress Biotech Inc stockEx-Dividend Date Alerts & High Yield Portfolio Growth - earlytimes.in
(FBIOP) Risk Channels and Responsive Allocation - Stock Traders Daily
Investors Still Aren't Entirely Convinced By Fortress Biotech, Inc.'s (NASDAQ:FBIO) Revenues Despite 28% Price Jump - 富途牛牛
Is Fortress Biotech Inc.(CNB0) stock resilient in recession scenarios2025 Market WrapUp & AI Powered Market Trend Analysis - Улправда
Fortress Biotech (NASDAQ: FBIO) registers 600,000 shares for Oaktree resale - Stock Titan
What momentum indicators show for Fortress Biotech Inc. stockJuly 2025 Big Picture & Weekly Setup with High ROI Potential - Улправда
Triplex vaccine enters Phase 2 trial in stem cell donors - MSN
Fortress Biotech’s CUTX-101 NDA resubmission accepted by FDA - MSN
Fortress Biotech (FBIO) files for 600K share offering by selling stockholders - StreetInsider
Investors Still Aren't Entirely Convinced By Fortress Biotech, Inc.'s (NASDAQ:FBIO) Revenues Despite 27% Price Jump - simplywall.st
Fortress Biotech (NASDAQ:FBIO) Shares Pass Above Two Hundred Day Moving AverageTime to Sell? - MarketBeat
Fortress Biotech (NASDAQ:FBIO) Shares Pass Above Two Hundred Day Moving Average – Time to Sell? - Defense World
Fortress Biotech (Nasdaq: FBIO) resale filing covers 600,000 shares for Oaktree - Stock Titan
Fortress Biotech Amends Credit Agreement with Oaktree - TipRanks
ATXI SEC FilingsAvenue Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Fortress Biotech (NASDAQ: FBIO) extends loan maturity and grants warrants - Stock Titan
Fortress Biotech, Inc. Enters into First Amendment to Credit Agreement - marketscreener.com
Fortress Biotech, Inc. and Cyprium Therapeutics, Inc. Announce FDA Acceptance of CUTX-101 NDA Resubmission - marketscreener.com
FDA sets new PDUFA date for Fortress Biotech’s Menkes disease therapy - Investing.com Nigeria
Fortress Biotech Rises After FDA Accepts Application for Menkes Treatment - marketscreener.com
Fortress Biotech, Cyprium announce FDA acceptance of CUTX-101 NDA resubmission - TipRanks
Fortress Biotech, Cyprium get FDA acceptance for CUTX-101 NDA resubmission - marketscreener.com
Fortress Biotech, Cyprium Get FDA Acceptance for CUTX-101 NDA Resubmission - TradingView — Track All Markets
Fortress Biotech’s CUTX-101 NDA Resubmission Accepted by FDA - TipRanks
Fortress Biotech (FBIO) Resubmits Application for Menkes Disease Treatment - GuruFocus
Fortress Biotech Announces FDA Acceptance of CUTX-101 NDA Resubmission - TradingView — Track All Markets
[8-K] Fortress Biotech, Inc. Reports Material Event | FBIO SEC FilingForm 8-K - Stock Titan
Fortress Biotech and Cyprium Therapeutics Announce FDA Acceptance of CUTX-101 NDA Resubmission - GlobeNewswire
Fortress Biotech, Inc. (NASDAQ:FBIO) Q3 2025 Earnings Call Transcript - MSN
Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi™ (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology - GlobeNewswire
(FBIOP) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Published on: 2025-12-08 06:59:10 - moha.gov.vn
FBIOP | Fortress Biotech, Inc. 9.375% Stock Data, Price & News - Quiver Quantitative
Fortress Biotech (NASDAQ:FBIO) Share Price Passes Above 200 Day Moving AverageTime to Sell? - MarketBeat
Fortress Biotech (NASDAQ:FBIO) Share Price Passes Above 200 Day Moving Average – Time to Sell? - Defense World
Avenue Therapeutics (NASDAQ: ATXI) 2025 proxy on director elections, KPMG audit and Fortress control - Stock Titan
Is Fortress Biotech Inc.(CNB0) stock undervalued historicallyWeekly Trading Summary & Pattern Based Trade Signal System - Newser
Fortress Biotech Inc Azioni (FBIO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.90%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):